Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 4;9(1):47.
doi: 10.1186/s13643-020-01307-8.

Salvage therapy for progressive, treatment-refractory or recurrent pediatric medulloblastoma: a systematic review protocol

Ashley A Adile  1   2 , Michelle M Kameda-Smith  1   3 , David Bakhshinyan  1   2 , Laura Banfield  4 , Sabra K Salim  1   2 , Forough Farrokhyar  3   5 , Adam J Fleming  6
Affiliations

Salvage therapy for progressive, treatment-refractory or recurrent pediatric medulloblastoma: a systematic review protocol

Ashley A Adile et al. Syst Rev. .

Abstract

Background: Central nervous system tumors remain the leading cause of cancer-related mortality amongst children with solid tumors, with medulloblastoma (MB) representing the most common pediatric brain malignancy. Despite best current therapies, patients with recurrent MB experience have an alarmingly high mortality rate and often have limited therapeutic options beyond inadequate chemotherapy or experimental clinical trials. Therefore, a systematic review of the literature regarding treatment strategies employed in recurrent pediatric MB will evaluate previous salvage therapies in order to guide future clinical trials. The aim of this systematic review will be to investigate the efficacy and safety of salvage therapies for the management of children with progressive, treatment-refractory, or recurrent MB.

Methods: We will conduct literature searches (from 1995 onwards) in MEDLINE, EMBASE, ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, and Cochrane Central Register of Controlled Trials. Studies examining the survival and toxicity of therapies administered to treatment-refractory pediatric MB patients will be included. Two reviewers will independently assess the search results based on predefined selection criteria, complete data abstraction, and quality assessment. The primary outcomes of this review will be overall and progression-free survival. Secondary outcomes will include safety and toxicity of each therapy administered. The study methodological quality (or bias) will be appraised using an appropriate tool. Due to the nature of the research question and published literature, we expect large inter-study heterogeneity and therefore will use random effects regression analysis to extract the combined effect. In additional analyses, we will investigate the role of re-irradiation and mono- vs. poly-therapy in recurrent disease, and whether molecular subgrouping of MB influences salvage therapy.

Discussion: This systematic review will provide an overview of the current literature regarding salvage therapies for relapsed MB patients. Investigation of clinically tested therapies for children with recurrent MB has significant implications for clinical practice. By reviewing the efficacy and toxicity of MB salvage therapies, this study will identify effective therapeutic strategies administered to recurrent MB patients and can inform future clinical trials aimed to improve patient survivorship and quality of life.

Systematic review registration: PROSPERO CRD42020167421.

Keywords: Children; Medulloblastoma; Recurrent disease; Salvage therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Northcott Paul A., Jones David T. W., Kool Marcel, Robinson Giles W., Gilbertson Richard J., Cho Yoon-Jae, Pomeroy Scott L., Korshunov Andrey, Lichter Peter, Taylor Michael D., Pfister Stefan M. Medulloblastomics: the end of the beginning. Nature Reviews Cancer. 2012;12(12):818–834. doi: 10.1038/nrc3410. - DOI - PMC - PubMed
    1. Pui Ching-Hon, Gajjar Amar J., Kane Javier R., Qaddoumi Ibrahim A., Pappo Alberto S. Challenging issues in pediatric oncology. Nature Reviews Clinical Oncology. 2011;8(9):540–549. doi: 10.1038/nrclinonc.2011.95. - DOI - PMC - PubMed
    1. Siegel Rebecca, Naishadham Deepa, Jemal Ahmedin. Cancer statistics, 2012. CA: A Cancer Journal for Clinicians. 2012;62(1):10–29. - PubMed
    1. Frühwald MC, Rutkowski S. Tumors of the central nervous system in children and adolescents. Dtsch Arztebl Int. 2011. 10.3238/arztebl.2011.0390. - PMC - PubMed
    1. Dolecek T. A., Propp J. M., Stroup N. E., Kruchko C. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2005-2009. Neuro-Oncology. 2012;14(suppl 5):v1–v49. doi: 10.1093/neuonc/nos218. - DOI - PMC - PubMed